Thumbnail
Access Restriction
Open

Author Twelves, C. J. ♦ Gardner, C. ♦ Flavin, A. ♦ Sludden, J. ♦ Bono, J. De ♦ Beale, P. ♦ Vasey, P. ♦ Hutchison, C. ♦ Macham, M. A. ♦ Rodriguez, A. ♦ Bleehen, N. M. ♦ Dennis, I. ♦ Judson, I.
Source PubMed Central
Content type Text
Publisher Nature Publishing Group
File Format PDF
Date Created 2002-09-05
Copyright Year ©1999
Language English
Difficulty Level Medium
Subject Domain (in DDC) Technology ♦ Medicine & health ♦ Diseases
Subject Keyword Cancer Research ♦ Oncology
Abstract DACA, also known as XR5000, is an acridine derivative active against both topoisomerase I and II. In this phase I study, DACA was given as a 3-h intravenous infusion on 3 successive days, repeated every 3 weeks. A total of 41 patients were treated at 11 dose levels between 9 mg m−2 d−1 and the maximum tolerated dose of 800 mg m−2 day−1 . The commonest, and dose-limiting, toxicity was pain in the infusion arm. One patient given DACA through a central venous catheter experienced chest pain with transient electrocardiogram changes, but no evidence of myocardial infarction. At the highest dose levels, several patients also experienced flushing, pain and paraesthesia around the mouth, eyes and nose and a feeling of agitation. Other side-effects, such as nausea and vomiting, myelosuppression, stomatitis and alopecia, were uncommon. There was one minor response but no objective responses. DACA pharmacokinetics were linear and did not differ between days 1 and 3. The pattern of toxicity seen with DACA is unusual and appears related to the mode of delivery. It is possible that higher doses of DACA could be administered using a different schedule of administration. © 1999 Cancer Research Campaign
ISSN 15321827
Age Range above 22 year
Educational Use Research
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 1999-06-01
Rights Holder Nature Publishing Group
e-ISSN 15321827
Journal British Journal of Cancer
Volume Number 80
Issue Number 11
Page Count 6
Starting Page 1786
Ending Page 1791


Open content in new tab

   Open content in new tab
Source: PubMed Central